{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-116005","form_type":"8-K","ticker":"CARM","cik":"0001485003","company_name":"Carisma Therapeutics Inc.","filed_at":"2023-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.211736+00:00","generated_at":"2026-06-08T06:31:38.139503+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Carisma Therapeutics reports Q3 2023 net loss of $21.4M; cash $94.1M funds into Q1 2025","bullets":["Net loss of $21.4M for Q3 2023 vs. $18.3M for Q3 2022.","Cash, cash equivalents and marketable securities of $94.1M as of Sept 30, 2023.","R&D expenses $19.6M, up $4.0M YoY, driven by CT-0525 preclinical costs.","Selected clinical candidate for CT-1119 (anti-mesothelin CAR-Monocyte); IND targeted for 2025.","Updated Phase 1 data for CT-0508 shows safety and biomarker correlation with stable disease."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-116005","json":"https://secwatch.observer/filing/0001104659-23-116005.json","markdown":"https://secwatch.observer/filing/0001104659-23-116005.md","text":"https://secwatch.observer/filing/0001104659-23-116005.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1485003/000110465923116005/0001104659-23-116005-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1485003/000110465923116005/tm2330254d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T06:31:38.139503+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b33b6dd30a5347b494aacd1133ab34d67af3f936","claim":"Carisma Therapeutics Inc. reported the quarter ended September 30, 2023 results: net income Net loss was $21.4 million for the third quarter of 2023, compared to net loss of $18.3 million for the same period in 2.","evidence_excerpt":"Carisma Therapeutics Inc. (the \"Company\") announced its financial results for the quarter ended September 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1485003/000110465923116005/0001104659-23-116005-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2023"},{"label":"Net income","value":"Net loss was $21.4 million for the third quarter of 2023, compared to net loss of $18.3 million for the same period in 2"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}